MANUEL CAITANO DIAS FERREIRA MAIA
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- A comprehensive review of immunotherapies in prostate cancer(2017) MAIA, Manuel Caitano; HANSEN, Aaron R.Prostate cancer is the second most common malignant neoplasm in men worldwide and the fifth cause of cancer-related death. Although multiple new agents have been approved for metastatic castration resistant prostate cancer over the last decade, it is still an incurable disease. New strategies to improve cancer control are needed and agents targeting the immune system have shown encouraging results in many tumor types. Despite being attractive for immunotherapies due to the expression of various tumor associated antigens, the microenvironment in prostate cancer is relatively immunosuppressive and may be responsible for the failures of various agents targeting the immune system in this disease. To date, sipuleucel-T is the only immunotherapy that has shown significant clinical efficacy in this setting, although the high cost and potential trial flaws have precluded its widespread incorporation into clinical practice. Issues with patient selection and trial design may have contributed to the multiple failures of immunotherapy in prostate cancer and provides an opportunity to tailor future studies to evaluate these agents more accurately. We have reviewed all the completed immune therapy trials in prostate cancer and highlight important considerations for the next generation of clinical trials.
conferenceObject Efficacy and tolerability of Docetaxel in patients with metastatic castrate-resistant prostate cancer older than 70 years compared with younger patients(2015) MAIA, M. C. Dias Ferreira; FRAILE, N. Moreno Perez; LAGE, L. Valente; SOUZA, R. Barosso; DZIK, C.; BASTOS, D. Assed; VAISBERG, V. Van- Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer(2017) MAIA, Manuel Caitano; PEREIRA, Allan A. Lima; LAGE, Liana Valente; FRAILE, Natalia Moreno; VAISBERG, Victor Van; KUDO, Guilherme; BARROSO-SOUSA, Romualdo; BASTOS, Diogo Assed; DZIK, CarlosPurpose Limited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxel as first-line chemotherapy for patients with mCRPC who were treated in our institution. Materials and Methods We retrospectively identified patients with mCRPC and a Karnosfky performance status of 60% or greater treated with docetaxel on any schedule as first-line chemotherapy between 2008 and 2013. The primary end point was a comparison of median overall survival (OS) according to age in this population. Secondary end points were comparisons of the rates of severe toxicities, prostate-specific antigen (PSA) decline of 50% or greater, and time to progression (TTP). Results were stratified by three age groups: younger than 65 years, 65 to 74 years, and 75 years or older. Results Among the 197 patients included, 68 (34%) were younger than 65 years, 85 (43%) were 65 to 74 years, and 44 (22%) were 75 years or older. The mean number of comorbidities was not different among groups (1.19 v 1.32 v 1.43; P = .54). Patients younger than 65 years received a higher cumulative dose of docetaxel (450 mg/m(2)v 382 mg/m(2)v 300 mg/m(2); P = .004). The rates of PSA decline of 50% or greater (41% v 47% v 36.4%; P = .51) and the median TTP (5.13 v 5.13 v 4.7 months; P = .15) were comparable among all groups. The median OS was longer in the group of patients younger than age 65 years (19.6 v 12.4 v 12.3 months; P = .012). Rates of any grade 3 or higher adverse event were not different among groups (63.2% v 71.8% v 54.5%; P = .14). Conclusion Administration of docetaxel in elderly patients who had good performance status was well tolerated. Rates of PSA decline and TTP were similar to those of younger patients, but median survival was lower. (C) 2017 by American Society of Clinical Oncology
conferenceObject EGFR GENOTYPING AND EPIDEMIOLOGY, CLINICAL AND PATHOLOGICAL FEATURES IN 191 PATIENTS WITH METASTATIC PULMONARY ADENOCARCINOMA IN SAO PAULO - BRAZIL.(2013) CASTRO JR., Gilberto; TAKAHASHI, Tiago K.; CAIRES-LIMA, Rafael; PROTASIO, Bruno M.; MAIA, Manuel C. D. F.; SOARES, Ibere C.; ROITBERG, Felipe S. R.; MARINI, Andrea M.; MARTINS, Renata E.; TAKAGAKI, Teresa Y.; ARAUJO, Pedro H. X. N.; TERRA, Ricardo M.; SHIANG, Christina; SIQUEIRA, Sheila A. C.; MELLO, Evandro S.; ALVES, Venancio A.; HOFF, Paulo M.article Biomarkers for Renal Cell and Urothelial Carcinoma(2016) DIZMAN, Nazli; HSU, Joann; BERGEROT, Paulo; MAIA, Manuel Caitano; PAL, Sumanta K.Although current and emerging treatment regimens are gaining traction in renal cell carcinoma (RCC) and bladder cancer, experts admit that the development of biomarkers to identify patients who will best respond to these treatments is still in a state of flux. In a presentation at the New York GU(TM) : 9th Annual Interdisciplinary Prostate Cancer Congress (R) and other Genitourinary Malignancies conference, Sumanta K. Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the state of biomarker development in the field of genitourinary malignancies. AJHO interviewed Dr Pal after his presentation. Dr Pal and colleagues provided additional commentary after the interview, which is included in this article.- Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden(2017) MAIA, Manuel Caitano; BERGEROT, Paulo Gustavo; DIZMAN, Nazli; HSU, JoAnn; JONES, Jeremy; LANMAN, Richard B.; BANKS, Kimberly C.; PAL, Sumanta K.Background: In a series of 224 patients with advanced renal cell carcinoma (RCC), we have previously reported circulating tumor DNA (ctDNA) detection in 79% of patients. Clinical factors associated with detection are unknown. Methods: Data was obtained from patients with radiographically confirmed stage IV RCC who received ctDNA profiling as a part of routine clinical care using a CLIA-certified platform evaluating 73 genes. Detailed clinical annotation was performed, including assessment of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, previous and current treatments and calculation of tumor burden using scan data most proximal to ctDNA assessment. Tumor burden was equated to the sum of longest diameter (SLD) of all measurable lesions. Results: Thirty-four patients were assessed (18 male and 16 female) with a median age of 62 (range, 34-84). Twenty-six patients, 4 patients and 4 patients had clear cell, sarcomatoid and papillary histologies, respectively. IMDC risk was good, intermediate and poor in 14, 19 and 1 patient, respectively. ctDNA was detected in 18 patients (53%) with a median of 2 genomic alterations (GAs) per patient. No associations were found between IMDC risk, histology or treatment type and presence/absence of ctDNA. However, patients with detectable ctDNA had a higher SLD compared to patients with no detectable ctDNA (8.81 vs 4.49 cm; P = 0.04). Furthermore, when evaluated as a continuous variable, number of GAs was correlated with SLD (P = 0.01). Conclusions: With the caveat of a limited sample size, it appears that SLD (a surrogate for tumor burden) is higher in mRCC patients with detectable ctDNA. Confirmation of these findings in larger series is ongoing and may suggest a capability for ctDNA to either complement or supplant radiographic assessment.
- Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).(2018) MAIA, Manuel C.; ALMEIDA, Lorena; BERGEROT, Paulo Gustavo; DIZMAN, Nazli; PAL, Sumanta K.
conferenceObject POLYMORPHISMS IN THE EXON 20 OF EGFR GENE IN METASTATIC LUNG ADENOCARCINOMA: PROGNOSTIC RELEVANCE AND SENSITIVITY TO ERLOTINIB.(2013) CASTRO JR., Gilberto; SOARES, Ibere C.; TAKAHASHI, Tiago K.; MAIA, Manuel C. D. F.; CAIRES-LIMA, Rafael; PROTASIO, Bruno M.; TAKAGAKI, Teresa Y.; SHIANG, Christina; MELLO, Evandro S.; HOFF, Paulo M.; ALVES, Venancio A.- Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden(2017) MAIA, Manuel Caitano; BERGEROT, Paulo Gustavo; DIZMAN, Nazli; HSU, Joann; JONES, Jeremy; CHOUEIRI, Toni K.; SONPAVDE, Guru; LANNNAN, Richard B.; BANKS, Kimberly; PAL, Sumanta K.